Gary E. Meininger
Impact in
- Endocrinology, Diabetes and Metabolism top 0.02%
- Diabetes Treatment and Management
- Diabetes Management and Research
- Nephrology top 0.5%
- Chronic Kidney Disease and Diabetes
Papers in
-
- Diabetes Treatment and Management 68
- Diabetes Management and Research 12
-
- HIV-related health complications and treatments 7
- Co-authors
- William J. Canovatchel (15 shared papers)Keith Usiskin (13 shared papers)Mehul G. Desai (16 shared papers)William T. Cefalu (6 shared papers)Dainius A. Balis (7 shared papers)Ujjwala Vijapurkar (18 shared papers)Kaj Stenlöf (5 shared papers)Maria Alba (10 shared papers)
- Journals
- Canadian Journal of Diabetes (13 papers)Diabetes Obesity and Metabolism (10 papers)Current Medical Research and Opinion (8 papers)Diabetes Care (7 papers)Diabetologia (3 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Gary E. Meininger
82 papers receiving 12.9k citations
Gary E. Meininger's Hit Papers
Peers
Comparison fields: 5 of 120
- Endocrinology, Diabetes and Metabolism 10.2k
- Nephrology 1.3k
- Pharmacology 1.3k
- Surgery 3.3k
- Emergency Medicine 358
Countries citing papers authored by Gary E. Meininger
This map shows the geographic impact of Gary E. Meininger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gary E. Meininger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gary E. Meininger more than expected).
Fields of papers citing papers by Gary E. Meininger
This network shows the impact of papers produced by Gary E. Meininger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gary E. Meininger. The network helps show where Gary E. Meininger may publish in the future.
Co-authors
The 25 scholars most cited alongside Gary E. Meininger, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 83 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy Hit paper breakdown → | 2019 | 4586 |
| 2 | Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone Hit paper breakdown → | 2006 | 668 |
| 3 | Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial Hit paper breakdown → | 2013 | 647 |
| 4 | Efficacy and safety of the dipeptidyl peptidase‐4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double‐blind, non‐inferiority trial Hit paper breakdown → | 2007 | 550 |
| 5 | Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise Hit paper breakdown → | 2012 | 542 |
| 6 | Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease Hit paper breakdown → | 2013 | 434 |
| 7 | Canagliflozin Compared With Sitagliptin for Patients With Type 2 Diabetes Who Do Not Have Adequate Glycemic Control With Metformin Plus Sulfonylurea Hit paper breakdown → | 2013 | 431 |
| 8 | Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial Hit paper breakdown → | 2013 | 425 |
| 9 | Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus Hit paper breakdown → | 2015 | 376 |
| 10 | 2016 | 292 | |
| 11 | 2013 | 289 | |
| 12 | 2013 | 288 | |
| 13 | 2015 | 270 | |
| 14 | 2014 | 234 | |
| 15 | 2014 | 231 | |
| 16 | 2014 | 202 | |
| 17 | 2014 | 198 | |
| 18 | 2014 | 197 | |
| 19 | 2011 | 186 | |
| 20 | 2013 | 145 |
About Gary E. Meininger
Gary E. Meininger is a scholar working on Endocrinology, Diabetes and Metabolism, Emergency Medicine, Surgery, Family Practice and Virology, having authored 83 papers that have together received 13.5k indexed citations. Recurring topics across this work include Diabetes Treatment and Management (68 papers), Pancreatic function and diabetes (16 papers), Diabetes Management and Research (12 papers), HIV-related health complications and treatments (7 papers), Metabolism, Diabetes, and Cancer (4 papers), Pancreatitis Pathology and Treatment (3 papers), Pharmacology and Obesity Treatment (3 papers) and HIV Research and Treatment (3 papers). The work is most often cited by research in Endocrinology, Diabetes and Metabolism (10.2k citations), Nephrology (1.3k citations), Pharmacology (1.3k citations), Surgery (3.3k citations) and Emergency Medicine (358 citations). Gary E. Meininger has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include William J. Canovatchel, Keith Usiskin, Mehul G. Desai, William T. Cefalu, Dainius A. Balis, Ujjwala Vijapurkar, Kaj Stenlöf, Maria Alba, Christine Kong-Yan Tong and Vlado Perkovic. Their work appears in journals such as Canadian Journal of Diabetes, Diabetes Obesity and Metabolism, Current Medical Research and Opinion, Diabetes Care and Diabetologia.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.